John Meady

Utilities Active Runners: Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), AES Corp (NYSE:AES), Exelon Corporation (NYSE:EXC), PG&E Corporation (NYSE:PCG)

Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) had its stock coverage assumed at Goldman Sachs Group Inc (NYSE:GS). The firm assigned buy rating on the stock. That positive rating of the stock came hot on the heels of the upgrade from Zacks, where analysts at Zacks assigned neutral on the stock from underperform. Companhia Energetica Minas…

Read More

Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the…

Read More

NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for…

Read More

Healthcare Stocks to Watch: TrovaGene (NASDAQ:TROV), AstraZeneca plc (ADR) (NYSE:AZN), Life Partners Holdings Inc. (NASDAQ:LPHI), Alliance HealthCare Services Inc. (NASDAQ:AIQ)

TrovaGene (NASDAQ:TROV) reported that for Q4, it narrowed its loss year over year, beating Street estimates, while revenue fell versus the prior year period and fell short of analysts’ expectations. The development-stage molecular diagnostic company reported a Q4 net loss of $1 million, or $0.05 per share, compared with the prior-year period’s net loss of…

Read More